547 related articles for article (PubMed ID: 24782154)
1. [Tofacitinib].
Döker S; Dewenter M; El-Armouche A
Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
Cohen SB; Koenig A; Wang L; Kwok K; Mebus CA; Riese R; Fleischmann R
Clin Exp Rheumatol; 2016; 34(1):32-6. PubMed ID: 26575982
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.
Bannwarth B; Kostine M; Poursac N
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):753-61. PubMed ID: 23570265
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
Curtis JR; Schulze-Koops H; Takiya L; Mebus CA; Terry KK; Biswas P; Jones TV
Clin Exp Rheumatol; 2017; 35(3):390-400. PubMed ID: 28079500
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
Yamaoka K; Tanaka Y
Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Gupta AK; Cernea M; Lynde CW
Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
[TBL] [Abstract][Full Text] [Related]
10. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
Sonomoto K; Yamaoka K; Kubo S; Hirata S; Fukuyo S; Maeshima K; Suzuki K; Saito K; Tanaka Y
Rheumatology (Oxford); 2014 May; 53(5):914-8. PubMed ID: 24441153
[TBL] [Abstract][Full Text] [Related]
11. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Cohen S; Radominski SC; Gomez-Reino JJ; Wang L; Krishnaswami S; Wood SP; Soma K; Nduaka CI; Kwok K; Valdez H; Benda B; Riese R
Arthritis Rheumatol; 2014 Nov; 66(11):2924-37. PubMed ID: 25047021
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of tofacitinib for the treatment of psoriatic arthritis.
Abdulrahim H; Sharlala H; Adebajo AO
Expert Opin Pharmacother; 2019 Nov; 20(16):1953-1960. PubMed ID: 31456440
[No Abstract] [Full Text] [Related]
13. Tofacitinib for treatment of rheumatoid arthritis.
Rakieh C; Conaghan PG
Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
Li ZG; Liu Y; Xu HJ; Chen ZW; Bao CD; Gu JR; Zhao DB; An Y; Hwang LJ; Wang L; Kremer J; Wu QZ
Chin Med J (Engl); 2018 Nov; 131(22):2683-2692. PubMed ID: 30425195
[TBL] [Abstract][Full Text] [Related]
16. Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis.
Ann Intern Med; 2013 Aug; 159(4):I-26. PubMed ID: 24026272
[No Abstract] [Full Text] [Related]
17. [JAK inhibitor].
Yamaoka K; Tanaka Y
Nihon Rinsho; 2013 Jul; 71(7):1243-7. PubMed ID: 23961674
[TBL] [Abstract][Full Text] [Related]
18. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
Sonomoto K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
[TBL] [Abstract][Full Text] [Related]
19. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
20. [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
Varisco PA; So A
Rev Med Suisse; 2014 Jan; 10(414):187-91. PubMed ID: 24624736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
